65,437 trials
Thyroid Gland Anaplastic Carcinoma
Primary: (Phase II) Overall Survival — 37.1; 29.0 percentage of participants — p=0.2831
Cancer of Kidney · Kidney Cancer · Renal Cancer
Primary: Positive Predictive Value (PPV) of 124I-cG250 Based on Positron-Emission Tomography/Computed Tomography (PET/CT) Imaging in the Detection of Clear Cell Renal Cell…
Lichen Planus
Primary: Change in Oral Sensitivity — -4.5; -6.0 score on a scale
Cardiac Arrythmias
Primary: Tp-e — 69.5; 74.7 milliseconds
Adult Women · Metastatic Breast Cancer · Estrogen Receptor Positive
Primary: Change in Serum 25(OH)D — 32 ng/ml — p=<0.01
Fecal Incontinence · Bowel Incontinence
Primary: Change From Baseline St. Mark's (Vaizey) Score — -2.8; -3.3; -4.3; -4.1 units on a scale
GIST
Primary: Efficacy of Avapritinib Based on Progression-free Survival (PFS) Determined by Central Radiological Assessment Per Modified Response Evaluation Criteria in Solid Tumors…
Cardiovascular Risk Factor
Primary: Changes in Plasma Levels of Fasting Trimethylamine-N-oxide (TMAO), a Choline Metabolite — 2.0; 1.9; 2.3; 2.6 uM — p=0.20
Follicular Lymphoma
Primary: Overall Response Rate (ORR) — 87.1; 87.5 percentage
Hormone-Resistant Prostate Cancer · Metastatic Prostate Carcinoma · Recurrent Prostate Carcinoma
Primary: Change in Tissue Testosterone and Dihydrotestosterone — 0.156 pg/mg
Castration Resistant Prostate Cancer
Primary: Clinical Benefit of NRX 194204 in Men With Castration- and Taxane-resistant Metastatic Prostate Cancer — 19 Participants
Multiple Myeloma
Primary: Change in Serum Osteocalcin From Baseline to End of Study in Patients With Relapsed/Refractory Multiple Myeloma. — 20.00 ng/ML
Breast Cancer
Primary: Clinical Benefit Rate of the Combination of Enzalutamide/ Fulvestrant — 7 Participants
Smoking
Primary: Total Cigarettes Smoked Per Day — 21.6; 7.7; 18.4; 12.5 number of cigarettes
OCD
Primary: Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale. — 4 Participants